news

Cipla Health Strengthens ProlyteORS Portfolio with Launch of Masala Guava Flavour

MUMBAI, India, March 24, 2026 /PRNewswire/ -- ProlyteORS, the W.H.O. recommended Oral Rehydration Salt (ORS) formulation from Cipla Health Limited, has…

7 days ago

Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE Cell-Therapy Platform Toward First-in-Human Study

Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetesCARY, N.C. and NEW YORK,…

7 days ago

Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials

New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug developmentHUNTSVILLE, Ala. and HAMBURG, Germany,…

7 days ago

HERE Technologies joins DCSA+ as first mapping and location intelligence partner advancing digital standards in container trade

Amsterdam – HERE Technologies, the leading mapping and location data platform, today announced that it has joined DCSA+, the partnership programme…

7 days ago

ONERugged Vehicle-Mounted Computer V82T Launches to Transform Fleet Management

SHENZHEN, China, March 24, 2026 (GLOBE NEWSWIRE) -- ONERugged, a brand of Emdoor Information Co., Ltd., recently introduced the V82T,…

7 days ago

ConnectingtheWorld,DrivingApexGrowth:ApexmindSummit2026SuccessfullyHeldinHongKong

HongKong, March 24, 2026 (GLOBE NEWSWIRE) -- The Apexmind Summit 2026 was grandly held in Hong Kong today. The summit…

7 days ago

Protean ‘Digital Disruptors 2026’ honours visionary leaders redefining India’s financial ecosystem

ETBrandEquity.com and Protean eGov Technologies recognise trailblazers driving digital public infrastructure (DPI), embedded finance, and regulatory innovation across India's financial…

7 days ago

Aptia and UST Earn ISG Paragon Award for Transformative Partnership

Partnership paves the way for disrupting traditional QA modelsBENGALURU, India and LONDON, March 24, 2026 /PRNewswire/ -- UST, a leading…

7 days ago

Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease…

1 week ago

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting…

1 week ago